Treatment-resistant depression's expanding options
Esketamine, psilocybin programs, and rTMS are reshaping how treatment-resistant depression is managed.
Treatment-resistant depression has options now that did not exist a decade ago. The barrier is rarely the science - it is the interventional psychiatry infrastructure and the payer pathway that gates access.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.